Abstract：Objective: To analyze the effect of mexiletine combined with Shensong Yangxin capsule on therapeutic effect and cardiac function in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated with arrhythmia. Methods: 178 NSTEMI outpatients with arrhythmia from June 2015 to June 2018 in our hospital were selected as the research subjects. According to the randomized parallel control design and simple random grouping method, the patients were divided into control group treated with mexiletine and study group treated with mexiletine combined with Shensong Yangxincapsule, with 89 cases in each group. The clinical efficacy, electrocardiogram indexes, cardiac function indexes before and after treatment and adverse reactions during treatment were compared between the two groups. Results: The total effective rate of the study group was 97.75%, which was significantly increased compared with 86.52% of the control group (P<0.05). Compared with before treatment, standard diviation of NN intervals (SDNN) and standard diviation average of NN intervals (SDANN) were significantly increased in both groups after treatment (P<0.05), but there was no significant difference between the study group and the control group after treatment (P>0.05). Compared with before treatment, the levels of left ventricular ejection fraction (LVEF), left ventricular systolic diameter (LVDs) and left ventricular diastolic diameter (LVDd) in the two groups were significantly increased after treatment, and the levels in the study group were significantly increased compared with control group after treatment(P<0.05). The incidence of adverse reactions was 3.37% in the study group and 6.74% in the control group, which showed no significant difference between the two groups (P>0.05). Conclusion: Mexiletine combined with Shensong Yangxin capsule can effectively improve the clinical efficacy of NSTEMI patients with arrhythmia. It plays an important role in improving cardiac function and anti-arrhythmia, and does not cause serious adverse reactions. It suggests that this therapy has good drug safety and is worthy of clinical application.
王枫, 马凤云, 赵希哲. 美西律联合参松养心胶囊对NSTEMI合并心律失常患者疗效和心功能的影响[J]. 河北医学, 2019, 25(7): 1085-1087.
WANG Feng, MA Fengyun, ZHAO Xizhe. Effect of Mexiletine Combined with Shensong Yangxin Capsule on Heart Function and Therapeutic Effect of NSTEMI Patients with Arrhythmia. HeBei Med, 2019, 25(7): 1085-1087.
[1] Liu Z, Zhao L, Li Y, et al.Evaluation of early interventional treatment opportunity of the elderly & high-risk patients with non-ST segment elevation acute myocardial infarction[J].Pak Med Sci,2015,31(5):1053~1056. [2] 牛洪梅.急性心肌梗死合并缓慢心律失常应用临时起搏器治疗的临床疗效分析[J].河北医学,2017,23(12):1984~1988. [3] 王莹,齐丽平.参松养心胶囊联合美托洛尔辨治气虚瘀阻证冠心病心律失常的临床观察[J].成都中医药大学学报,2016,39(2):86~89. [4] 梁峰,沈珠军,方全,等.2014年美国心脏协会/美国心脏病学院关于非ST抬高急性冠脉综合征患者治疗指南(一)[J].中国心血管病研究,2015,13(7):596~601. [5] Patel RB, Tannenbaum S, Viana-Tejedor A, et al.Serum potassium levels, cardiac arrhythmias and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36[J].Eur Heart Acute Cardiovasc Care,2017,6(1):18~25. [6] Otuki S, Hasegawa K, Watanabe H, et al.The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias[J].Electrocardiol,2017,50(3):277~281. [7] 张秀敏,武艳丽,黄文霞,等.丹红注射液联合参松养心胶囊治疗急性心肌梗死心力衰竭的疗效及对炎症因子的影响[J].中西医结合心脑血管病杂志,2018,16(8):1064~1068. [8] 简鹏,李庆海,范立华,等.甘松新酮对快速性心律失常大鼠心肌细胞抑制作用的实验研究[J].中国临床药理学杂志,2015,31(22):2240~2242. [9] 周开珩,黄芸.人参皂苷Rb3治疗心肌梗死的分子生物学研究[J].实用药物与临床,2017,20(11):1236~1239.
2019, Vol. 25 
冀公网安备13080202000677号